Comparative Efficacy of Endoscopic Sleeve Gastroplasty (Esg) Versus Liraglutide in Weight Loss and Remission Of Obesity-Related Comorbidities: Twelve Months Follow-Up Results

What Was Tested

This randomized controlled trial paper looks at Liraglutide in the context of fat loss, obesity & body recomposition.

Liraglutide, a glucagon-like peptide-1 agonist, has been successfully used for weight loss and remission of comorbidities in patients with obesity.

So far, there are no clinical studies comparing short-term outcomes in patients treated with ESG or Liraglutide.

Who Took Part

According to the abstract, 43 patients were involved.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

A total of 43 patients with class I and II obesity were included in the study.

Twenty-three patients underwent ESG, and 20 patients were treated with Liraglutide.

How the Study Was Run

The researchers set it up as a randomized study.

The patients were allocated by chance, so the Liraglutide group and the comparison group should start out alike.

A prospective, randomized controlled, monocentric study was performed.

All participants received standardized follow-up protocols with assessments by both surgeon and nutritionist in the bariatric ambulatory setting.

Weight loss outcomes, including the percentage of excess weight loss (%EWL), total weight loss (%TWL), and resolution of obesity-related comorbidities were assessed at 3, 6, and 12 months post-intervention.

What Was Measured

So far, there are no clinical studies comparing short-term outcomes in patients treated with ESG or Liraglutide.

PubMed files the paper under topics including Liraglutide, Weight Loss, Gastroplasty, Obesity, Morbid, Hypoglycemic Agents and Obesity.

The authors tagged it with the keywords Bariatric surgery and Endoscopic sleeve gastroplasty.

What This Means in Plain Language

The paper is a randomized study of Liraglutide in 43 patients in people with fat loss, obesity & body recomposition.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Obesity surgery), a journal based in United States.

More context: the Liraglutide compound page, Fat loss, obesity & body recomposition research.